vimarsana.com

Latest Breaking News On - Viktor drvota - Page 13 : vimarsana.com

Karolinska Development s portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients

STOCKHOLM, Sweden, May 2, 2022. Karolinska Development AB announces that its portfolio company Biosergen is preparing a Phase 2 clinical trial of the company’s lead compound BSG005, targeting. | May 2, 2022

Karolinska institutetJohan dighedViktor drvotaEu pressKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmGeneral counselKarolinska development ab publ stock exchangePress releaseOmpound kdev se0002190926

Investegate |Karolinska Development AB (pub Announcements | Karolinska Development AB (pub: Karolinska Development s portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients

Investegate announcements from Karolinska Development AB (pub, Karolinska Development’s portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients

Karolinska institutetJohan dighedViktor drvotaKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmGeneral counselInvestegate announcementsInvestegate company announcementsKarolinska development ab pubLobenewswire and globenewswire

Karolinska Development AB (publ): Karolinska Development s portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients

STOCKHOLM, Sweden, May 2, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen is preparing a Phase 2 clinical trial of the company's lead compound BSG005

Karolinska institutetJohan dighedViktor drvotaKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmGeneral counsel

Karolinska Development AB (publ): Karolinska Development s portfolio company OssDsign completes patient enrolment to the TOP FUSION study

STOCKHOLM, SWEDEN, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has enrolled all patients in the clinical study TOP FUSION, which

Karolinska institutetJohan dighedViktor drvotaInvestment fundKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmOssdsign catalystGeneral counsel

Karolinska Development AB (publ): Karolinska Development s portfolio company Promimic s IPO offering fully subscribed

STOCKHOLM, Sweden, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic's IPO offering was fully subscribed. Promimic is now provided with

Karolinska institutetJohan dighedViktor drvotaChalmers university of technologyKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmNasdaq first north growthNasdaq first north growth marketGeneral counselChalmers university

vimarsana © 2020. All Rights Reserved.